Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be
This article was originally published in The Tan Sheet
Executive Summary
Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.
You may also be interested in...
Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split
Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.
Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split
Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.
Pfizer's OTC, Nutritional Businesses Could Be Looking For A New Home
Pfizer's consumer and nutritional businesses soon may be for sale, but the timing may not be right for the most likely buyers, market analysts say.